ION-994
- Generic Name
- ION-994
A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx in Participants With Chronic Heart Failure With Reduced Ejection Fraction
- Conditions
- Chronic Heart Failure With Reduced Ejection Fraction
- Interventions
- Drug: Placebo
- First Posted Date
- 2021-04-08
- Last Posted Date
- 2023-09-11
- Lead Sponsor
- Ionis Pharmaceuticals, Inc.
- Target Recruit Count
- 72
- Registration Number
- NCT04836182
- Locations
- ๐ต๐ฑ
Indywidualna Specjalistyczna Praktyka Lekarska, Lodz, Poland
๐ญ๐บSemmelweis Egyetem - Varosmajori Sziv es Ergyogyaszati Klinika, Budapest, Hungary
๐บ๐ธArkansas Cardiology, Little Rock, Arkansas, United States
A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx in Hypertensive Participants With Uncontrolled Blood Pressure
- First Posted Date
- 2021-01-19
- Last Posted Date
- 2025-02-18
- Lead Sponsor
- Ionis Pharmaceuticals, Inc.
- Target Recruit Count
- 160
- Registration Number
- NCT04714320
- Locations
- ๐บ๐ธ
Nature Coast Clinical Research - Crystal River, Crystal River, Florida, United States
๐บ๐ธEagle Clinical Research, Chicago, Illinois, United States
๐บ๐ธHolston Medical Group, Kingsport, Tennessee, United States
A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx
- First Posted Date
- 2019-09-10
- Last Posted Date
- 2023-01-18
- Lead Sponsor
- Ionis Pharmaceuticals, Inc.
- Target Recruit Count
- 26
- Registration Number
- NCT04083222
- Locations
- ๐บ๐ธ
National Research Institute - Wilshire, Los Angeles, California, United States
๐บ๐ธMidwest Institute for Clinical Research, Indianapolis, Indiana, United States
๐บ๐ธCentral Alabama Research, Birmingham, Alabama, United States
A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx, an Antisense Inhibitor Administered Subcutaneously to Hypertensive Participants With Controlled Blood Pressure
- First Posted Date
- 2018-10-22
- Last Posted Date
- 2023-01-06
- Lead Sponsor
- Ionis Pharmaceuticals, Inc.
- Target Recruit Count
- 25
- Registration Number
- NCT03714776
- Locations
- ๐บ๐ธ
Ohio Clinical Research - Lyndhurst, Lyndhurst, Ohio, United States
๐บ๐ธOrange County Research Center, Tustin, California, United States
๐บ๐ธProgressive Medical Research, Port Orange, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.